Peru Astrazeneca Laboratory Tender

The Director for Andean Countries of the AstraZeneca laboratory Allan Aldana has confirmed that Peru has been included as a country where Phase III studies will be carried out to obtain the vaccine against Covid-19 which is being developed in conjunction with the Oxford University.The Oxford - AstraZeneca vaccine is one of the most advanced among more than 140 alternatives being developed around the world. The talks between Peru and said company began in July and their confirmation is a sign of the confidence that exists in our country to effectively carry out these tests in their final stage before beginning their worldwide distribution.To this end the National Institute of Health and the General Directorate of Medicines Supplies and Drugs DIGEMID of the Ministry of Health are committed to provide support in the procedures for obtaining permits and licenses that allow starting with these tests in the coming days in our country.The tests that will be carried out in Peru will be an extension of the Phase III studies that this pharmaceutical company has been carrying out in the United States and for which it is expected to have the participation of 30000 volunteers. In this sense we already have the approval of BARDA Biomedical Advanced Research and Development Authority and the FDA Food and Drug Administration so that Phase III of the studies that are being carried out in the United States are expanded and included to Peru.This multisectoral effort is a sign of the firm commitment of the Government of Peru aimed at ensuring timely access to the vaccine against Covid-19 to all Peruvians.